TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.

The Motley Fool Logo The Motley Fool By Keith Speights
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.

Novo Nordisk reduced its 2025 sales and profit guidance due to slower growth in GLP-1 diabetes and obesity drugs, facing challenges from compounded medications and increased competition from Eli Lilly.

Insights
GM   neutral

Used as a comparative benchmark for valuation metrics, with a much lower P/E ratio than Ferrari


NVO   negative

Downgraded full-year outlook for fourth time, lost 9% global market share, facing competition and compounding challenges